Pre-Clinical Study and Phase 1 Trial of Pi3-Kinase Inhibitors in the Treatment of Newly Diagnosed Glioblastoma

Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma

A Morokoff, W Ng, A Gogos, A Kaye

2015-08-01

We discuss a number of recent developments that have led to new concepts regarding the biology of gliomas. Collective tissue banki..

Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme

DV Brown, PM Daniel, GM D'Abaco, A Gogos, W Ng, AP Morokoff, T Mantamadiotis

2015-01-01

Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype in Glioblastoma Multiforme (GB..

Complexities of lysophospholipid signalling in glioblastoma

W Ng, A Pébay, K Drummond, A Burgess, AH Kaye, A Morokoff

2014-01-01

Glioblastoma multiforme (GBM) is the most malignant brain tumour and continues to have a very poor median survival of 12-16 months..